The bradykinin-2 receptor antagonist, icatibant, improves lung function in patients with SARS-CoV2 associated ARDS - First results of a prospective off-label use patient-related observational study.
- DOI
- 10.5061/dryad.f4qrfj6wg
- Published
- 2021
- Container
- Not recorded
- Publisher
- Dryad
- Open access
- yes
Credibility signals
limited evidence Score 47/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- supportingPublication license: A publication license was supplied: https://creativecommons.org/publicdomain/zero/1.0/legalcode. Presence improves reuse transparency, not research validity.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.5061/dryad.f4qrfj6wg,
title = {The bradykinin-2 receptor antagonist, icatibant, improves lung function in patients with SARS-CoV2 associated ARDS - First results of a prospective off-label use patient-related observational study.},
author = {Tebbe, Johannes and Kulamadayil-Heidenreich, Nidhi-Su-Ann and Heidenreich, Holger and Gielen, Stephan and Hansen, Torsten},
year = {2021},
doi = {10.5061/dryad.f4qrfj6wg},
url = {https://doi.org/10.5061/dryad.f4qrfj6wg}
}RIS
TY - JOUR TI - The bradykinin-2 receptor antagonist, icatibant, improves lung function in patients with SARS-CoV2 associated ARDS - First results of a prospective off-label use patient-related observational study. AU - Tebbe, Johannes AU - Kulamadayil-Heidenreich, Nidhi-Su-Ann AU - Heidenreich, Holger AU - Gielen, Stephan AU - Hansen, Torsten PY - 2021 DO - 10.5061/dryad.f4qrfj6wg UR - https://doi.org/10.5061/dryad.f4qrfj6wg ER -
APA
Johannes, T., Nidhi-Su-Ann, K., Holger, H., Stephan, G., & Torsten, H. (2021). The bradykinin-2 receptor antagonist, icatibant, improves lung function in patients with SARS-CoV2 associated ARDS - First results of a prospective off-label use patient-related observational study.. https://doi.org/10.5061/dryad.f4qrfj6wg